Mozart Therapeutics to Present Research on Novel CD8 T Cell Network at Upcoming Meetings: Digestive Disease Week® 2023 (DDW 2023) and IMMUNOLOGY 2023TM AAI Annual Meeting
SEATTLE, WA. April 25, 2023 — Mozart Therapeutics, a leading developer of therapeutic CD8 Treg Modulators for the treatment of autoimmune and inflammatory disease, today announced it will present at two upcoming conferences: Digestive Disease Week® taking place May 6-9, 2023 in Chicago, IL and Immunology 2023TM AAI Annual Meeting, taking place May 11-15 in Washington D.C.
Presentation details are as follows:
Digestive Disease Week® (DDW)
Title: A Novel Bispecific CD8 Treg Modulator Targeting Cytolytic CD8 Regulatory T Cells Reduces Pathogenic CD4 T Cells and Inflammation in Translational Models of Intestinal Autoimmune and Inflammatory Disease
Presentation number: 3860987
Date/Time: Sunday, May 7, 12:30 to 1:30 p.m., ET
Presenter: Cathy McMahan, PhD, VP, Non-Clinical Development
Immunology AAI 2023
Title: Pre-clinical Pharmacologic and Tolerability Characterization of a Novel KIR x CD8 Targeting Bispecific CD8 Treg Modulator
Presentation number: 2638
Date/Time: Friday, May 12, 2:30 p.m. to 3:45 p.m., ET
Presenter: Minh Pham, PhD, Principal Scientist, Non-Clinical Development
Title: A KIR x CD8 Targeting Bispecific Modulator Enhances Regulatory CD8 T Cell Functions, and Reduces Inflammation in Models of Autoimmune Disease
Presentation number: 2804
Date/Time: Friday, May 12, 2:30 p.m. to 3:45 p.m., ET
Presenter: Jennifer Gardell, PhD, Associate Director, Translational Research
All presentations will be available on the Science page of the Mozart website.
About CD8 Treg Modulators
CD8 Treg Modulators are disease modifying therapeutic molecules that selectively target the CD8 regulatory T cell network to counteract early events in the autoimmune inflammatory cascade. The dysregulation of this network is believed to play a key role in the pathology of autoimmune and inflammatory disease. CD8 Treg Modulators are designed to restore the intrinsic functions of CD8 T regulatory cells to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and other inflammatory diseases.
About Mozart Therapeutics
Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory CD8 T regulatory cell network. The therapeutic focus of Mozart’s lead program is autoimmune mediated gastro-intestinal disorders. The company is headquartered in Seattle, WA. For more information visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx.
Media Contact:
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219